Over the last 20 years the development of new therapies aimed at tackling the most major chronic neurodegenerative diseases (NDD) has been filled with promise and setbacks. The complexity associated with targeting neurological diseases has led to some big pharma players retreating from brain drug research, yet the recent technological and clinical advancements exhibit potential to address the ever-growing demand. Having observed notable milestones to date in neurology and potential innovative mechanisms of action, Edison Group anticipate that we may only be a few positive studies away from the launch of the next generation of breakthrough NDD medicines.
Коментарі